Literature DB >> 18629555

Endocrine dysfunction in leprosy.

A M O Leal1, N T Foss.   

Abstract

Leprosy is still an endemic disease, especially in Third World countries, and, because of migration, it still persists in Europe and the United States. The disease affects the peripheral nerves, skin, and multiple internal organs, making its clinical recognition difficult. In particular, the endocrine manifestations caused by leprosy have been underestimated, even by specialists. The endocrine changes present in leprosy include hypogonadism, sterility, and osteoporosis. In addition, the spectral immune nature of leprosy offers an attractive model to investigate the pathogenetic correlation between the patterns of inflammation in the poles of its spectrum and the hormonal disarrangements observed in this disease. It is important that those involved in leprosy management be aware of the potential endocrine changes and their treatment to address the disease in all of its aspects. In this article, we review the findings on endocrine dysfunction in leprosy, including a survey of the literature and of our own work.

Entities:  

Mesh:

Year:  2008        PMID: 18629555     DOI: 10.1007/s10096-008-0576-5

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  103 in total

Review 1.  Androgens and estrogens modulate the immune and inflammatory responses in rheumatoid arthritis.

Authors:  Maurizio Cutolo; Bruno Seriolo; Barbara Villaggio; Carmen Pizzorni; Chiara Craviotto; Alberto Sulli
Journal:  Ann N Y Acad Sci       Date:  2002-06       Impact factor: 5.691

2.  LEPROUS ORCHITIS IN REACTIONAL BORDERLINE CASES.

Authors:  C K JOB; V P MACADEN
Journal:  Int J Lepr       Date:  1963 Jul-Sep

3.  Leprosy, hypercalcemia, and elevated serum calcitriol levels.

Authors:  V N Hoffman; O M Korzeniowski
Journal:  Ann Intern Med       Date:  1986-12       Impact factor: 25.391

Review 4.  The role of interleukin-6 in the human adrenal gland.

Authors:  G Päth; W A Scherbaum; S R Bornstein
Journal:  Eur J Clin Invest       Date:  2000-12       Impact factor: 4.686

5.  Evidence that increased circulating 1 alpha, 25-dihydroxyvitamin D is the probable cause for abnormal calcium metabolism in sarcoidosis.

Authors:  N H Bell; P H Stern; E Pantzer; T K Sinha; H F DeLuca
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

6.  WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients.

Authors:  C G Iyer; J Languillon; K Ramanujam; G Tarabini-Castellani; J T De las Aguas; L M Bechelli; K Uemura; V Martinez Dominguez; T Sundaresan
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

7.  Hypercalcemia in leprosy.

Authors:  E Ryzen; F R Singer
Journal:  Arch Intern Med       Date:  1985-07

8.  Ovarian function in female patients with multibacillary leprosy.

Authors:  Khanna Neena; A C Ammini; Manjula Singh; Ravindra Kumar Pandhi
Journal:  Int J Lepr Other Mycobact Dis       Date:  2003-06

9.  Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis.

Authors:  J S Adams; O P Sharma; M A Gacad; F R Singer
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

Review 10.  Stress-hyperglycemia, insulin and immunomodulation in sepsis.

Authors:  Paul E Marik; Murugan Raghavan
Journal:  Intensive Care Med       Date:  2004-02-26       Impact factor: 17.440

View more
  9 in total

1.  Arthritis, progressive maculopapular rash and severe peripheral neuropathy in a 60-year-old man. Diagnosis: Leprosy.

Authors:  François Tremblay; Martin Albert
Journal:  CMAJ       Date:  2013-12-23       Impact factor: 8.262

2.  Risk factors for leprosy reactions in three endemic countries.

Authors:  David M Scollard; Celina M T Martelli; Mariane M A Stefani; Maria de Fatima Maroja; Laarni Villahermosa; Fe Pardillo; Krishna B Tamang
Journal:  Am J Trop Med Hyg       Date:  2014-12-01       Impact factor: 2.345

Review 3.  Management of osteoporosis in the aging male: focus on zoledronic acid.

Authors:  Paul K Piper; Ugis Gruntmanis
Journal:  Clin Interv Aging       Date:  2009-06-29       Impact factor: 4.458

4.  Ancient DNA study reveals HLA susceptibility locus for leprosy in medieval Europeans.

Authors:  Ben Krause-Kyora; Marcel Nutsua; Lisa Boehme; Federica Pierini; Dorthe Dangvard Pedersen; Sabin-Christin Kornell; Dmitriy Drichel; Marion Bonazzi; Lena Möbus; Peter Tarp; Julian Susat; Esther Bosse; Beatrix Willburger; Alexander H Schmidt; Jürgen Sauter; Andre Franke; Michael Wittig; Amke Caliebe; Michael Nothnagel; Stefan Schreiber; Jesper L Boldsen; Tobias L Lenz; Almut Nebel
Journal:  Nat Commun       Date:  2018-05-01       Impact factor: 14.919

5.  Circulating levels of insulin-like growth factor-I (IGF-I) correlate with disease status in leprosy.

Authors:  Luciana Silva Rodrigues; Mariana Andrea Hacker; Ximena Illarramendi; Maria Fernanda Miguens Castelar Pinheiro; José Augusto da Costa Nery; Euzenir Nunes Sarno; Maria Cristina Vidal Pessolani
Journal:  BMC Infect Dis       Date:  2011-12-13       Impact factor: 3.090

6.  Endocrine dysfunction in patients of leprosy.

Authors:  Rohit Kumar Singh; Rohit Bhasin; Y S Bisht; K V S Hari Kumar
Journal:  Indian J Endocrinol Metab       Date:  2015 May-Jun

7.  Endocrinological Testicular Dysfunction in Patients with Lepromatous Leprosy and the Impact of Disease on Patient's Quality of Life.

Authors:  Alpana Mohta; Aditi Agrawal; Pritee Sharma; Arti Singh; Smiley Garg; Ramesh Kumar Kushwaha; Suresh Kumar Jain
Journal:  Indian Dermatol Online J       Date:  2020-09-19

8.  The clinical & neurophysiological study of leprosy.

Authors:  Murat Cabalar; Vildan Yayla; Samiye Ulutas; Songul Senadim; Ayla Culha Oktar
Journal:  Pak J Med Sci       Date:  2014-05       Impact factor: 1.088

Review 9.  Natural selection and infectious disease in human populations.

Authors:  Elinor K Karlsson; Dominic P Kwiatkowski; Pardis C Sabeti
Journal:  Nat Rev Genet       Date:  2014-04-29       Impact factor: 53.242

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.